A research analysis published in Neuromodulation: Technology at the Neural Interface concluded that clinicians should consider spinal cord stimulation (SCS) earlier than as a last resort for the treatment of complex regional pain syndrome (CRPS). SCS has been FDA-approved for the treatment of neuropathic trunk and limb pain since 1989 and involves a slender electrical lead implanted under the skin of the back to deliver a mild electrical current to the spinal cord. The analysis found that to facilitate functional rehabilitation in CRPS, SCS should be considered as soon as more conservative therapies have failed – after perhaps three months. Read a news report here.
Posted on August 4, 2013